

Appl. No. 09/615,736
Reply to Office Action of October 21, 2003

Attorney Docket: P65773US0

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

Claims 1-15 (Canceled)

Claim 16 (Currently Amended): A formulation consisting essentially of ~~at least one EFA selected from the group consisting of: gamma linolenic acid; dihomogammalinolenic acid; arachidonic acid; adrenic acid; docosapentaenoic acid; stearidonic acid; eicosatetraenoic acid (n-3); eicosapentaenoic acid (EPA) or derivative; docosapentaenoic acid (n-3) and docosahexaenoic acid, at least one homocysteine lowering agent selected from the group consisting of: vitamin B12; folic acid, at a maximum daily dose of 5 mg; and vitamin B6, at a maximum daily dose of 20 mg; and, optionally, at least one antioxidant.~~

Claim 17 (Previously Amended): The formulation of claim 16, wherein the formulation is a pharmaceutical formulation.

Claim 18 (Original): The formulation of claim 16, wherein the formulation is a nutritional formulation.

Claim 19 (Original): The formulation of claim 16, wherein the formulation is in the form of a hard gelatin capsule or a soft gelatin capsule.

Claims 20 – 21 (Canceled)

Claim 22 (Currently Amended): The formulation of claim 16, wherein the homocysteine-lowering agent is 5 mg of vitamin B12 ~~the EPA or derivative has a purity of more than 90%~~.

Appl. No. 09/615,736
Reply to Office Action of October 21, 2003

Attorney Docket: P65773US0

Claim 23 (Currently Amended): The formulation of claim 16, wherein ~~the at least one~~ ~~EFA is a eicosapentaenoic acid (EPA) the EPA or derivative has a purity of more than 95%.~~

Claim 24 (Currently Amended): The formulation of claim ~~23~~ ~~16~~, wherein ~~the eicosapentaenoic acid (EPA) or derivative~~ is the ethyl ester form or the pure tri-EPA triglyceride form.

Claim 25 (Currently Amended): The formulation of claim 16, ~~wherein the EFA is arachidonic acid having 500mg of EPA, 1 mg of hydroxocobalamin, 1mg of folic acid and 2mg of pyridoxine.~~

Claim 26 (Currently Amended): The formulation of claim 16, ~~wherein the EFA is gammalinolenic acid or dihomogammalinolenic acid having 500mg of EPA, 1 mg of hydroxocobalamin, 1mg of folic acid and 5mg of pyridoxine.~~

Claims 27 – 36 (Cancelled)

Claim 37 (Currently Amended): The formulation of claim 16, wherein folic acid is ~~the only homocysteine lowering agent replaced by methyltetrahydrofolate.~~

Claim 38 (Original): The formulation of claim 16, wherein the formulation is in a form suitable for oral administration.

Claim 39 (Currently Amended): The formulation of claim 16 having an antioxidant, wherein the antioxidant is selected from the group consisting of: natural, synthetic or semi-synthetic vitamin E; natural, synthetic or semi-synthetic coenzyme Q; natural, synthetic or semi-synthetic alpha-lipoic acid; and natural, synthetic or semi-synthetic vitamin C.

Claims 40-45 (Cancelled)

Claim 46 (Currently Amended): ~~The method of claim 44, wherein the A method for treating a subject suffering from one or more of the following conditions selected from the group consisting of:~~

Appl. No. 09/615,736
Reply to Office Action of October 21, 2003

Attorney Docket: P65773US0

- ____ (a) ~~a cardiovascular disorder; a cerebrovascular disorder; atherosclerosis; heart disease; cerebrovascular disease; stroke; peripheral vascular disease; thrombosis;~~
- ____ (b) ~~diabetes; pre diabetes (syndrome X); macrovascular complications of diabetes; microvascular complications of diabetes; cardiovascular disease; retinopathy; nephropathy; neuropathy;~~
- ____ (c) ~~a psychiatric disorder; schizophrenia; a schizotypal disorder; a and other schizopreniform disorders; bipolar disorder (mania, or manic depression); depression; a panic disorder; an anxiety disorder; a sleep disorder; a social phobia;~~
- ____ (d) ~~a neurological disorder; a neurodegenerative disorder; Alzheimer's disease; dementia; Parkinson's disease; multiple sclerosis; and Huntington's disease; chronic pain;~~
- ____ (e) ~~a kidney disorder;~~
- ____ (f) ~~an inflammatory or an immunological disorder of the gastrointestinal tract, the respiratory system, the skin and mucous membranes, or the joints or other tissues;~~
- ____ (g) ~~an eye or hearing disorder; age related macular degeneration; age related deafness; tinnitus;~~
- ____ (h) ~~obesity; or~~
- ____ (i) cancer which comprises administering to the subject the formulation of claim 16.

Claims 47 - 48 (Cancelled)